Enterprise Value
145.6M
Cash
13.47M
Avg Qtr Burn
-9.493M
Short % of Float
5.86%
Insider Ownership
36.15%
Institutional Own.
18.77%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Avasopasem Manganese (GC4419) Details Infectious disease, COVID-19 | Failed Discontinued | |
Rucosopasem Details Cancer, Non-small cell lung carcinoma | Failed Discontinued | |
Rucosopasem Details Pancreatic cancer, Cancer | Failed Discontinued | |
Avasopasem Manganese (GC4419) Details Head and neck cancer, Cancer | Failed Discontinued | |
Avasopasem Manganese (GC4419) Details Lung cancer, Esophagitis, Non-small cell lung carcinoma | Failed Discontinued |